Researchers at the Ragon Institute of Mass General Brigham, MIT, and Harvard have developed a new malaria vaccine strategy that targets previously overlooked regions of the PfCSP protein. Published in the Journal of Experimental Medicine, the study suggests that combining current vaccine proteins with specific short peptides can significantly reduce the number of parasites reaching the liver.
Current malaria prevention relies heavily on two World Health Organization-recommended vaccines, RTS,S and R21. While these are helpful interventions, public health officials note they do not work as well or as long as desired. The gap in efficacy stems from a biological blind spot: both vaccines target the same region of the malaria parasite’s PfCSP protein—a long stretch of repeated amino acids known as the major repeat.
The PfCSP Protein Blind Spot
The PfCSP protein is not a uniform surface. While the major repeat is easy for the immune system to recognize, two other regions—the minor repeat and the junction—are harder to reach but trigger the strongest anti-malarial antibodies found to date.
Neither the minor repeat nor the junction is included in existing vaccines. To test if current vaccines might trigger antibodies against these regions incidentally, researchers Ja-Hyun Koo and Prabhanshu Tripathi used mouse models carrying human antibody genes. They found that when mice received the same piece of PfCSP used in R21, only the major repeat cells responded; the cells capable of producing stronger antibodies against the other regions remained dormant.
Even providing the full PfCSP protein did not solve the problem, as the major repeat essentially drowned out
the other regions, preventing the immune system from noticing the more effective targets.
A Peptide-Based Fix for Immune Response
To bypass this competition, the Ragon Institute team shifted their approach. Instead of the whole protein, they utilized a short peptide—a fragment just long enough to display the minor repeat alone. Without the interference of the major repeat, the correct immune cells responded, multiplied, and developed the characteristics of mature protective antibodies.
The team then tested a combination strategy: the R21-style protein paired with two short peptides, one for the minor repeat and one for the junction. This method engaged all three cell types simultaneously. In subsequent tests, this combination was the only approach that significantly cut the number of parasites reaching the liver.
Working with the National Institutes of Health, Johns Hopkins University, and Columbia University, the researchers also discovered that the strength of the antibody’s grip is less important than the way it binds. They engineered versions that bound the parasite 10 times more tightly, but this did not result in better protection.
Implementation Gaps in Sub-Saharan Africa
The drive for more effective vaccines comes amid a worrying rise in malaria incidence. According to a review in Nature, malaria cases rose to 60.4 per 1,000 population at-risk in 2023, up from 58.6 in 2022. This resulted in 597,000 global deaths, with children under five accounting for roughly 20% of that mortality.
The burden is disproportionately felt in sub-Saharan Africa, where pregnant women and young children remain the most vulnerable. In 2023, approximately 12.4 million pregnancies (34% of the 36 million total) were infected with malaria in moderate and high endemic countries in the region. These infections can lead to maternal anemia, stillbirths, preterm births, and neonatal mortality.
Despite the availability of insecticide-treated nets (ITNs), prompt diagnosis, and the newer vaccines, implementation gaps persist. Factors hindering the uptake of these interventions include socioeconomic status, educational attainment, and frail health systems.
| Vulnerable Group | Primary Risks/Impacts | Recommended Interventions |
|---|---|---|
| Children Under 5 | High mortality (20% of global total) | Vaccines, ITNs, prompt diagnosis/treatment |
| Pregnant Women | Maternal anemia, stillbirth, low-birthweight | IPTp-SP, ITNs, early diagnosis |
The Ragon Institute’s findings suggest that rather than replacing current vaccines, it may be possible to add these peptides to existing protocols. This would give the immune system a reason to target the parts of the parasite it currently skips.
While the study provides a practical path toward improving vaccine efficacy, the transition from mouse models to human application remains the final hurdle. Human trials must occur before this combined peptide strategy can be implemented in the field.
Related reading
- BIC/FTC/TAF and Long-Acting ART Show Efficacy in Real-World HIV Data
- Northwestern University secures $20M for AI-driven protein engineering lab
- New Sanctions Package Targets 33 Cyber Actors and Entities (archyde.com)
- Korea’s AI Strategy: Integrating AI with Core Industries for Global Hegemony (archynewsy.com)
